GMGabriel Marengo

Gabriel Marengo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gabriel Marengo has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Family health history and pharmacogenomics show cross generation premature amitriptyline discontinuation is associated with CYP2C19 loss of-function enrichment

    by Emma F. Magavern, Gabriel Marengo, Maia Megase, Damian Smedley, Mark J. Caulfield

    Background: Genetics influence medication response yet integrating family health history (FHH) of medication response with pharmacogenomics remains underexplored. The objective of this study was to examine cross-generational medication exposure patterns and assess the utility of FHH for medication response using electronic health records. Methods: Genes & Health (G&H) data from Bangladeshi and Pakistani participants were analysed for parent-offspring trios with medication exposure. Premature discontinuation of amitriptyline was defined as discontinuation within three months. Logistic regression and Fisher’s exact test explored the relationship between parental discontinuation, offspring discontinuation, and CYP2C19 loss-of-function variants. Results: 13% of offspring prescriptions overlap with parental prescriptions, primarily short-term treatments (antibiotics, vaccines, steroids). In 96 trios, cross-generational amitriptyline exposure is observed. Parental discontinuation does not predict offspring discontinuation ( p = 0.275, OR 1.70). However, offspring with two-generation histories of early discontinuation are significantly enriched for CYP2C19 predicted poor metabolizers (38% vs. 10.5%, p = 0.049, OR 4.86). Conclusions: FHH of medication response can highlight individuals enriched for pharmacogenomic variants. This is a clinically useful finding, which may flag psychiatric patients with a two-generation history of early amitriptyline discontinuation or intolerance as a priority for pharmacogenomic testing. This study demonstrates the potential of integrating FHH into clinical pharmacogenomics for actionable insights.


  • Open Access

    The spectrum of gene intolerance to variation: Insights from a rare disease cohort

    by Pilar Cacheiro, Gabriel Marengo, David U. Gorkin, Kevin A. Peterson, Yonina Loskove, Stephen A. Murray, Damian Smedley

    Deciphering the spectrum of intolerance to loss-of-function (LoF) variation helps identify genes that are critical at various stages of development and hierarchical levels of organisation. We have previously combined cell and mouse viability screens for single-gene knockouts, to summarise this spectrum into discrete categories, Full Spectrum of Intolerance to Loss-of-function (FUSIL), from genes essential for cell proliferation to those where LoF has no phenotypic impact. Here, we expand on this analysis to uncover distinct patterns in gene expression across developmental stages in both mouse and human within these categories, as well as gene sequence and evolutionary features, protein functional classes, and disease associations. Further, by analysing data from diagnosed patients in a rare disease cohort, we gain insights into the relationships between variant de novo status, molecular consequence, mode of inheritance, and type of disorder in the FUSIL categories. These associations facilitate the identification of predicted pathogenic variants in genes not currently linked to Mendelian conditions.


  • Open Access

    Lethal phenotypes in Mendelian disorders

    by Pilar Cacheiro, Samantha Lawson, Ignatia B. Van Den Veyver, Gabriel Marengo, David Zocche, Stephen A. Murray, Michael Duyzend, Peter N. Robinson, Damian Smedley


  • Open Access

    Lethal phenotypes in Mendelian disorders

    by Pilar Cacheiro, Samantha Lawson, Ignatia B. Van Den Veyver, Gabriel Marengo, David Zocche, Stephen A. Murray, Michael Duyzend, Peter N. Robinson, Damian Smedley

    Essential genes are those whose function is required for cell proliferation and/or organism survival. A gene’s intolerance to loss-of-function can be allocated within a spectrum, as opposed to being considered a binary feature, since this function might be essential at different stages of development, genetic backgrounds or other contexts. Existing resources that collect and characterise the essentiality status of genes are based on either proliferation assessment in human cell lines, embryonic and postnatal viability evaluation in different model organisms, and gene metrics such as intolerance to variation scores derived from human population sequencing studies. There are also several repositories available that document phenotypic annotations for rare disorders in humans such as the Online Mendelian Inheritance in Man (OMIM) and the Human Phenotype Ontology (HPO) knowledgebases. This raises the prospect of being able to use clinical data, including lethality as the most severe phenotypic manifestation, to further our characterisation of gene essentiality. Here we queried OMIM for terms related to lethality and classified all Mendelian genes into categories, according to the earliest age of death recorded for the associated disorders, from prenatal death to no reports of premature death. To showcase this curated catalogue of human essential genes, we developed the Lethal Phenotypes Portal ( https://lethalphenotypes.research.its.qmul.ac.uk ), where we also explore the relationships between these lethality categories, constraint metrics and viability in cell lines and mouse. Further analysis of the genes in these categories reveals differences in the mode of inheritance of the associated disorders, physiological systems affected and disease class. We highlight how the phenotypic similarity between genes in the same lethality category combined with gene family/group information can be used for novel disease gene discovery. Finally, we explore the overlaps and discrepancies between the lethal phenotypes observed in mouse and human and discuss potential explanations that include differences in transcriptional regulation, functional compensation and molecular disease mechanisms. We anticipate that this resource will aid clinicians in the diagnosis of early lethal conditions and assist researchers in investigating the properties that make these genes essential for human development.